The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Condition:   Dry Eye Interventions:   Drug: Reproxalap Ophthalmic Solution (0.25%) QID;   Drug: Vehicle Ophthalmic Solution QID;   Drug: Reproxalap Ophthalmic Solution (0.25%) QID to BID;   Drug: Vehicle Ophthalmic Solution QID to BID Sponsor:   Aldeyra Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials